Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
338 results about "Risk groups" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
High-risk group. Epidemiology A group of people in the community with a higher-than-expected risk for developing a particular disease, which may be defined on a measurable parameter–eg, an inherited genetic defect, physical attribute, lifestyle, habit, socioeconomic and/or educational feature, as well as environment.
Methods and apparatus for selecting multiple paths taking into account shared risk
Methods, systems, computer readable media are provided which facilitate the selection of multiple paths through a network represented by a network topology which take into account shared risk which may exist between network resources. The method involves identifying a first path through the network topology from a source node to a destination node, the first path comprising a first sequence of network resources. For at least one shared risk group, a determination is made if any of the at least one shared risk group includes any of the first sequence of network resources, a shared risk group being a group of network resources within the network topology which have a shared risk. A topology transformation is performed of the network topology into a virtual topology which discourages the use of network resources in any shared risk group determined. A second path through the virtual topology is identified from the source node to the destination. The method may be adapted to encourage node and / or edge disjointness.
Owner:WSOU INVESTMENTS LLC +1
Diagnostic agent for ischemic heart disease risk group
InactiveUS20120122777A1Lower Level RequirementsSuppression problemBiocidePeptide/protein ingredientsDiagnostic agentAdditive ingredient
The present invention relates to a diagnostic agent for an ischemic heart disease risk group comprising an anti-brain-derived neurotrophic factor antibody as an effective ingredient, to an assay method for an ischemic heart disease risk group performed by measuring a brain-derived neurotrophic factor concentration in blood, and to a suppressive / preventive drug for ischemic heart disease, particularly for post-infarction myocardial remodeling, comprising a brain-derived neurotrophic factor.
Owner:MASAO DAIMON +1
Composite Profiles of Cell Antigens and Target Signal Transduction Proteins for Analysis and Clinical Management of Hematologic Cancers
InactiveUS20100261204A1Increased riskDetermining prognosisDisease diagnosisBlood/immune system cellsCellular antigensTarget signal
Owner:BECKMAN COULTER INC
Method of grouping and analyzing clinical risks, and system therefor
InactiveUS7127407B1Accurate estimateAccurate predictionMedical data miningFinanceDiseaseSeverity/Intensity
A comprehensive set of risk groups explicitly identifies groups of individuals with multiple interacting co-morbid conditions, and which explicitly identifies the severity of illness level. This allows accurate prediction of future health care resource needs of an entire population, while simultaneously helping the health care provider isolate problems to identify changes in care to reduce costs and improve quality.
Owner:3M INNOVATIVE PROPERTIES CO
Male multi-tumor marker detection protein chip and kit thereof
InactiveCN101603966AChemiluminescene/bioluminescenceBiological testingProtein markersProstate cancer
The invention discloses a male multi-tumor marker detection protein chip and a kit thereof. The chip comprises a substrate, protein markers distributed in an array type and point coatings of contrasts, wherein the substrate is a glass substrate or a film substrate; and the tumor markers and the point coatings of the contrasts are seven protein markers of AFP, CEA, NSE, CYFRA21-1, CA19-9, tPSA and SCC-ag, a positive contrast and a negative contrast which are uniformly distributed and latticed on the substrate. A reaction result of various indexes can be obtained only through one reaction by utilizing the protein chip, and the following tumors can be simultaneously screened: primary liver cancer, prostatic cancer, pancreatic cancer, lung cancer, esophageal cancer, gastric cancer and colorectal cancer. The invention is particularly suitable for the general examination of malignant tumors of male asymptomatic groups and high risk groups.
Owner:上海裕隆生物科技有限公司
Method for minimizing overdraft charge-off
A method for minimizing overdraft charge-off in a bank account includes:(a) identifying a plurality of factors that can result in a bank account charge-off;(b) building a case history database of bank account holder information based upon a plurality of data elements associated with each of the plurality of factors;(c) creating numeric and / or categorical representations of the bank account holder information for each of the bank accounts in the case history database;(d) tabulating the numeric and / or categorical representations and the data elements for the bank accounts in the case history database;(e) combining certain ones of the numeric and / or categorical representations to separate the bank accounts in the case history database into a plurality of risk groups, each risk group having an associated probability of charge-off; and(f) optimizing, for each of the plurality of risk groups, a bank profit, by setting overdraft limits.
Owner:CARREKER CORORATION A DELAWARE
Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers
InactiveUS20070105165A1Increased relapse riskDetermining prognosisDisease diagnosisBlood/immune system cellsCellular antigensTarget signal
The present invention is directed to methods for establishing a composite marker profile for a sample derived from an individual suspected having a neoplastic condition. A composite marker profile of the invention allows for identification of prognostically and therapeutically relevant subgroups of neoplastic conditions and prediction of the clinical course of an individual. The methods of the invention provide tools useful in choosing a therapy for an individual afflicted with a neoplastic condition, including methods for assigning a risk group, methods of predicting an increased risk of relapse, methods of predicting an increased risk of developing secondary complications, methods of choosing a therapy for an individual, methods of determining the efficacy of a therapy in an individual, and methods of determining the prognosis for an individual. In particular, the method of the present invention discloses a method for establishing a composite marker profile that can serve as a prognostic indicator to predict whether the course of a neoplastic condition in a individual will be aggressive or indolent, thereby aiding the clinician in managing the patient and evaluating the modality of treatment to be used. In particular embodiments disclosed herein, the methods of the invention are directed to establishing a composite marker profile for a leukemia selected from the group consisting of Chronic Lymphocytic Leukemia (CLL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), and Acute Lymphocytic Leukemia (ALL).
Owner:BECKMAN COULTER INC +4
Internet protocol fast reroute for shared risk link group failure recovery
InactiveUS20100315943A1Promote recoveryReduce decreaseError preventionTransmission systemsInternet protocol suiteShared risk link group
A scheme to achieve fast recovery from SRLG failures in the IP layer is described. An exemplary scheme, called multi-section shortest path first (“MSSPF”), builds on the idea of IP Fast Reroute (“IPFRR”), guarantees 100% recovery of SRLG failures and causes no dead loops. Given a source node, a destination node, and a shared risk group failure on a next hop from the source node to the destination node, failure recovery information may be determined by (1) accepting a graph representing network topology information including the source node and the destination node, (2) determining a node which is able to reach the destination node using a route which does not include the source node, wherein a path from the source node to the determined node is not affected by the shared risk group failure, and (3) storing, in association with the shared risk group failure, both (i) a network address associated with the determined node and (ii) an alternative output port of the source node using the shortest path from the source node to the determined node.
Owner:POLYTECHNIC INSTITUTE OF NEW YORK UNIVERSITY
Intelligent voice-controlled voiceprint and face authentication access control system and method
InactiveCN106097495AComfortable and easy-to-use experienceImprove security levelTwo-way working systemsIndividual entry/exit registersKey pressingDoorbell
The invention discloses an intelligent voice-controlled voiceprint and face authentication access control system and a method. The system includes a gate host, an indoor host and a central server. Through voice control, the system avoids picking up the key, pressing button, checking fingerprint or other complex operation, especially the awkwardness for opening the door when items are held in the hands; the voiceprint and face recognition are combined to achieve a high security level, which is more secure than the traditional key, password lock and fingerprint lock. The access control system provided by the invention has basically the same shape and use method as the traditional visual intercom access control system and the visual doorbell, and is easy to be accepted by users; compared with the traditional visual intercom access control system and the visual doorbell, the access control system provided by the invention has additional no disturb function, which can be set aiming at the unwanted visitors like salesman. The access control system provided by the invention has community joint defense and linkage function, the control center can timely transfer high risk warning information, and control the host to automatically and timely warn high-risk groups (wanted suspects, etc.), so as to effectively avoid the occurrence of malignant cases, and protect the safety of the user's life and property.
Owner:赵树龙
Method for minimizing overdraft charge-off
InactiveUS20090327123A1Minimizing overdraft charge-offFinancePayment architectureBank accountData element
A method for minimizing overdraft charge-off in a bank account includes:(a) identifying a plurality of factors that can result in a bank account charge-off;(b) building a case history database of bank account holder information based upon a plurality of data elements associated with each of the plurality of factors;(c) creating numeric and / or categorical representations of the bank account holder information for each of the bank accounts in the case history database;(d) tabulating the numeric and / or categorical representations and the data elements for the bank accounts in the case history database;(e) combining certain ones of the numeric and / or categorical representations to separate the bank accounts in the case history database into a plurality of risk groups, each risk group having an associated probability of charge-off; and(f) optimizing, for each of the plurality of risk groups, a bank profit, by setting overdraft limits.
Owner:CARREKER CORORATION A DELAWARE
Application method of long non-coding RNA (ribonucleic acid) CASC2 originated from serum exosomes
ActiveCN103993088AGood specificity for early diagnosisPredict disease riskMicrobiological testing/measurementExosomeBiochemistry
The invention discloses an application method of long non-coding RNA (ribonucleic acid) (LncRNA) CASC2 originated from serum exosomes, namely the LncRNA CASC2 originated from the serum exosomes is used for preparing preparations for screening and early diagnosis of a high-risk group of gliomas or prognosis of patients with the gliomas. Studies prove that the expression level of the LncRNA CASC2 is reduced by extracting the RNA after separating the exosomes in serum of the patients with the gliomas, performing reverse transcription and performing real-time fluorescence quantitative analysis. By utilizing the LncRNA CASC2 originated from the serum exosomes, the specificity for early diagnosis of the gliomas can achieve 85.7% and the sensitivity can achieve 97.1%. By detecting the expression level of the LncRNA CASC2 in the serum exosomes of the patients with the gliomas, early and fast non-invasive diagnosis can be performed on the patients with the gliomas.
Owner:CENT SOUTH UNIV
Method and system for assisting in screening lung cancer based on artificial intelligence
InactiveCN107247887AHelp to distinguishSpecial data processing applicationsPulmonary noduleMalignancy
A method and system based on artificial intelligence to assist lung cancer screening. By generating a model for distinguishing lung cancer and a benign and malignant evaluation model for pulmonary nodules, the basic information, basic health information, general living conditions, and current status of the subject are collected in real time during online detection. Respiratory symptoms, chronic disease and lung disease history and smoking status, and the risk value of cancer and the probability of malignancy of nodules were detected through the identification model of lung cancer and the evaluation model of benign and malignant pulmonary nodules. The present invention fully utilizes various related features, divides high- and low-risk groups of lung cancer and evaluates benign and malignant pulmonary nodules through multi-dimensional information, and can help to distinguish high-risk groups.
Owner:点内(上海)生物科技有限公司
A relevant failure prediction method and system
ActiveCN106021062AImprove execution efficiencyImprove usabilityHardware monitoringCharacter and pattern recognitionDependabilityRisk groups
The invention provides a relevant failure prediction method and system. The relevant failure prediction method comprises the steps of acquiring historical failure information of a distributive computing system and acquiring a failure information sample database according to the historical failure information; acquiring effective failure information in the failure information sample database and performing time discretization processing on the effective failure information to obtain a sample data matrix; acquiring a current probability shared risk group structure of the distributive computing system according to the sample data matrix; acquiring current failure sample information of the distributive computing system that is collected in real time; performing failure prediction on the distributive computing system according to the current probability shared risk group structure and the current failure sample information. The method and the system can describe the diversity and transmissibility characteristics of relevant failures comprehensively and accurately, improve prediction precision, effectively increase the prediction method execution efficiency and facilitate online failure deployment and implementation, and are of great importance for improving the availability and the reliability of the distributive computing system.
Owner:ZHUHAI POWER SUPPLY BUREAU GUANGDONG POWER GIRD CO
Shared risk group handling within a media gateway
ActiveUS20080317055A1Data switching by path configurationNetwork connectionsComputer networkRisk groups
A media gateway controller (MGC) is described herein that implements a shared risk group package to control and prevent a media gateway (MG) from establishing redundant links like a primary link and a secondary link that use resources that share the same risk of failure. Essentially, the MGC uses the shared risk group package to control which resources like ephemeral terminations are used by the MG to establish the primary link and the secondary link such that if any of the resources associated with the primary link fail then the secondary link remains operational within the MG and if any of the resources associated with the secondary link fail then the primary link remains operational within the MG.
Owner:TELEFON AB LM ERICSSON (PUBL)
ELISA reagent kit for screening, diagnosis and treatment effect forecast of nasopharyngeal carcinoma
The present invention discloses two antigen protein fragments of protein product Rta of nasopharyngeal specific gene BRLF1, encoding gene, recombinant carrier, fusion protein (GST and GST-R185-R150), nasopharyngeal cancer diagnosis agent containing the compounds and the ELISA agent box, as well as the application of the compounds in detection of EB virus in vitro. The ELISA agent box of the present invention can be used for nasopharyngeal cancer screening, early diagnosis and forecasts of treatment results. The present invention has the advantages of simplicity, sensitivity and specificity, and is suitable for early diagnosis and forecasts of nasopharyngeal carcinoma, and the large-scale screening of high-risk groups. The present invention is easy to be widely promoted and used; the use is safe and clean; the present invention has broad market prospects.
Owner:同昕生物技术(北京)有限公司
Method and apparatus for constructing a repair path around a non-available component in a data communications network
A method of constructing a repair path around a non-available component in a data communications network is described. The data communications network has, as components, nodes and links therebetween defining a network topology. The non-available component is a member of a shared risk group of components commonly renderable non-available. The method comprises the step, performed at a repairing node, of identifying as a repair target a neighbour component of the non-available component. The method further comprises the step of constructing a repair network topology omitting the shared risk group. The method further comprises the step of constructing a repair path to the repair target in the repair topology.
Owner:CISCO TECH INC
Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
InactiveUS20080201173A1Avoid it happening againData processing applicationsHealth-index calculationPharmacySide effect
Methods for delivering a drug to a patient in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
Owner:CELGENE CORP
Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated
InactiveUS20110166876A1Avoid it happening againData processing applicationsHealth-index calculationPharmacySide effect
Methods for delivering a drug to a patient in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved.
Owner:CELGENE CORP
Emergency linkage health monitoring system and method
The invention discloses an emergency linkage health monitoring system and method. The emergency linkage health monitoring system comprises a health detection underwear which comprises an underwear body. The underwear body is internally provided with a master control circuit and a power supply management circuit. The master control circuit comprises a low power consumption processor which is connected with a heartbeat sensor, a respiration sensor, a storage, a nine-shaft movement sensor, a positioning chip, a wireless communication circuit and a vibration motor. The wireless communication circuit comprises a first communication chip, a second communication chip and a third communication chip. The outer surface of the underwear body is further provided with an emergency alarm button connected with the low power consumption processor. The emergency linkage health monitoring system further comprises mobile equipment, an emergency platform and an intelligent household subsystem. By adoption of the emergency linkage health monitoring system and method, real-time and immediate active caring and salvation on the risk group are achieved.
Owner:浙江物云科技有限公司
Communication of a risk information in a multi-domain network
ActiveCN101399771AData switching networksSpecial data processing applicationsRisk identificationRisk groups
A method for communicating risk information within a network including a plurality of domains connected to one another at the border nodes of said domains, characterized by steps consisting of: determining a connection path within a first domain (2), said path running between a border node (N21 ) of the first domain connected to a second domain and a recipient node, determining a set of shared risk groups of the first domain which the connection path crosses, assigning a shared risk identification code to said connection path, storing, within a shared risk group management device (28) associated with the first domain, a data structure associating said shared risk identification code with said set of shared risk groups.
Owner:ALCATEL LUCENT SAS
Identifying, translating and filtering shared risk groups in communications networks
ActiveUS20140126355A1Error preventionFrequency-division multiplex detailsProgram instructionRisk groups
A method, apparatus, and computer-readable storage medium are disclosed for processing shared risk group (SRG) information in communications networks. The method includes obtaining at least one SRG identifier by processing SRG information included in network information received at a first network layer from a second network layer, and processing the at least one SRG identifier using one or more operations configured to ensure that the SRG identifier is unique among a plurality of SRG identifiers. The apparatus includes a network interface adapted to receive network information comprising SRG information, a processor coupled to the network interface, and a memory coupled to the processor and adapted to obtain at least one SRG identifier by processing the SRG information and to process the at least one SRG identifier. The computer-readable storage medium is configured to store program instructions that when executed are configured to cause a processor to perform the method.
Owner:CISCO TECH INC
Therapeutic agent comprising lipocalin 2 against cancer metastasis, and methods of early diagnosis and inhibition of cancer metastasis using lipocalin 2
InactiveUS20090311224A1Prevent proliferationGood treatment effectOrganic active ingredientsVirusesAbnormal tissue growthLymphatic Spread
The present invention relates to a pharmaceutical composition for the inhibition of cancer metastasis, more precisely, a novel pharmaceutical composition against cancer metastasis comprising lipocalin 2 protein, a gene encoding the protein, an expression vector containing the gene or cells transfected with the expression vector as an effective ingredient, a method for the inhibition of cancer metastasis using the composition, a diagnostic kit for the prediction of cancer metastasis, a method for the selection of a metastasis risk group using the kit, a novel pharmaceutical composition for the inhibition of cancer growth and a method for the inhibition of cancer growth using the same. The pharmaceutical composition of the present invention specifically inhibits cancer metastasis, so that it can improve the effect of cancer treatment dramatically. And, the diagnostic kit and the method for the selection of a metastasis risk group using the kit enable the selection of a metastasis risk group by measuring the level of lipocalin 2 in tumor tissues or in body fluid. Therefore, the kit and the method can contribute to the effective clinical control of a cancer patient. Further, the composition of the invention can be effectively used for the treatment of liver cancer owing to its liver cancer growth inhibitory effect.
Owner:MOGAM BIOTECH RES INST
Method and system for performing orthotopic liver transplantation prognosis condition grouping on hepatocellular carcinoma patient with single tumor
InactiveCN107180154AGood treatment effectGood for healthSpecial data processing applicationsMaximum diameterRegression analysis
The invention relates to a method for performing prognosis condition grouping on a hepatocellular carcinoma patient who has single tumor and is about to be subjected to or is already subjected to orthotopic liver transplantation. The method comprises the steps of (1) obtaining a sample from general samples after transhepatic biopsy before transplantation or liver transplantation, and detecting CK19 and GPC3 expression conditions of tumor cells in the hepatocellular carcinoma tissue sample of the patient; (2) detecting and recording a maximum diameter of the tumor of the patient; (3) detecting and recording a serum alpha-fetoprotein level of the patient; and (4) based on a pathological section, observing whether microvascular invasion exists or not. Recurrent risks are scored according to beta coefficients of four factors in COX regression analysis; scores in items are subjected to addition; a recurrent risk group with a total score less than or equal to 4 is determined as a low recurrent risk group; a recurrent risk group with a total score equal to 5-7 is determined as a medium recurrent risk group; and a current risk group with a total score more than or equal to 8 is determined as a high recurrent risk group. Through the method, an effective auxiliary information value can be provided for a doctor and the patient; and tumor recurrence or transfer is closely monitored, so that health conditions can be discovered within the shortest time, the doctor and the patient are effectively prompted, and people are reminded to timely examine body conditions.
Owner:冯德昭 +1
Autoantibody joint detection ELISA kit for early screening of esophageal squamous carcinoma
The invention belongs to the technical field of medical oncology, and particularly discloses an autoantibody joint detection ELISA kit for early screening of esophageal squamous carcinoma. The kit comprises a solid-phase carrier and a tumor-associated antigen coated on the solid-phase carrier, wherein the tumor-associated antigen consists of P53, TP53, CDKN2B and NPM1. Furthermore, the kit comprises sample diluent, a second antibody, second antibody diluent, positive control serum, negative control serum, developing solution, stop solution and washing solution. The ELISA kit is capable of effectively detecting the esophageal squamous carcinoma, especially the early esophageal squamous carcinoma, has detection sensitivity up to 88.8% and specificity up to 86.3%, can be used for the large-scale screening of asymptomatic groups in high-risk areas of the esophageal squamous carcinoma, and is beneficial for the esophageal squamous carcinoma screening and early discovery of the asymptomatichigh-risk groups.
Owner:THE FIRST AFFILIATED HOSPITAL OF ZHENGZHOU UNIV
Hilar cholangiocarcinoma patient prognosis prediction model
PendingCN107305596APredicted 3-year survival rateEasy to predictSpecial data processing applicationsHilar CholangiocarcinomasImproved survival
The invention relates to a prognosis prediction model for patients with hilar cholangiocarcinoma. Specifically, the present invention provides a carrier for postoperative prognosis of patients with hilar cholangiocarcinoma, which is used to calculate risk factor scores and patient 3-year survival rate Y3 and / or 5-year survival rate Y5; Wherein, the risk factors include at least the patient's age X, and the fraction of the patient's age, the 3-year survival rate and the 5-year survival rate satisfy the relationship described in the article. The present invention systematically investigates the clinical and pathological characteristics that affect the prognosis of patients with hilar cholangiocarcinoma, and the effect of patients after surgical treatment, evaluates the key factors that affect the survival and prognosis of patients with hilar cholangiocarcinoma, and establishes a method for patients with hilar cholangiocarcinoma. The list of survival prognosis is used to evaluate the 3-year and 5-year survival rate of patients after surgery, and to screen out high-risk groups for intervention to improve the survival prognosis of patients.
Owner:SHANGHAI INST OF BIOLOGICAL SCI CHINESE ACAD OF SCI +1
Sense-antisense gene pairs for patient stratification, prognosis, and therapeutic biomarkers identification
InactiveUS20160259883A1Quality improvementHighly prognostically significantMicrobiological testing/measurementLibrary screeningPrognostic signaturePatient stratification
The present invention relates to a method of identification of clinically and genetically distinct sub-groups of patients subject to a medical condition, particularly breast, lung, and colon cancer patients using a composition of respective gene expression values for certain gene pairs. Sense-antisense gene pairs (SAGPs) which are relevant for a medical condition and the disease prognosis are used by the method to generate statistical models based on the expression values of the SAGPs. SAGPs for which the statistical models are found to have high value in prognosis of the variation of medical condition and the diseases are selected and integrated in the prognostic signature including specified parameters (e.g. cut-off values) of the prognostic model. It further relates to using respective gene expression values for these genes to predict patient′ risk groups (in context of patient's survival or / and disease progression) and to using the predicted groups for identification of patient risk, and specific and robust prognostic biomarkers with mechanistic interpretations of biological changes (associated with the gene signatures) appropriating for an implementation of therapeutic targeting.
Owner:AGENCY FOR SCI TECH & RES
Use of recombinant mesenchymal stem cell in preparation of immunosuppressant
ActiveCN104800243ASuppress immune responseRetain anti-tumor abilityUnknown materialsOther foreign material introduction processesAbnormal tissue growthImmunologic disorders
The invention discloses a use of a recombinant mesenchymal stem cell in preparation of an immunosuppressant. The invention relates to the recombinant mesenchymal stem cell capable of expressing a chemokine receptor CCR7 on a cytomembrane. After infusion, the recombinant mesenchymal stem cells can be specifically transferred to a secondary lymphatic organ, and a large amount of the recombinant mesenchymal stem cells are gathered in a T cell enrichment region in the secondary lymphatic organ and can efficiently inhibit T cell immunoreaction. Through use of the recombinant mesenchymal stem cell in treatment on graft-versus-host disease after bone marrow transplantation, immunological rejection after organ transplantation and autoimmune diseases, a cost is reduced, a cell use amount is reduced and side-effects are relieved. In treatment, the recombinant mesenchymal stem cell retains tumor cell killing effects and provides a high efficiency and beneficial novel approach for clinical treatment on graft-versus-host disease after bone marrow transplantation, immunological rejection after organ transplantation and autoimmune diseases of tumor high-risk groups.
Owner:INST OF BASIC MEDICAL SCI ACAD OF MILITARY MEDICAL SCI OF PLA
Gene function association network-based method for discovering chronic disease mechanism and early warning intervention policy thereof
ActiveCN106126893AShow validityEpigenetic far-reachingHealth-index calculationProteomicsDisease riskCrowds
The present invention discloses a gene function association network-based method for discovering a chronic disease mechanism and an early warning intervention policy thereof. The method can be applied to the field of related research and application of biology, medicine and pharmacy. Epigenetic changes of the high-risk groups surveyed and discovered according to epidemiology before disease attack are detected, the epigenetic changes before the disease is associated with indicator gene changes of the disease through gene function network analysis, then a long-term molecular mechanism contributing to the disease risk is discovered, and risk early warning for the group, risky diagnosis for an individual, and indicators and methods for preventive intervention are provided. According to the method, a long-term steady biological path or biological function change may leave a mark on related gene epigenetic inheritance, and a chronic disease biological path or biological function level mechanism may be found through analysis of the synergistic effect of epigenetic differences.
Owner:ZHEJIANG UNIV
Cardio cerebrovascular rehabilitation training system
The invention belongs to the technical field of cardio cerebrovascular rehabilitation training, and discloses a cardio cerebrovascular rehabilitation training system. The cardio cerebrovascular rehabilitation training system comprises: a blood-pressure detecting module, a pulse detecting module, a heart rate detecting module, a main control module and a training module, an analysis module, a disease warning module, a data storage module, and a display module. The system can well group the populations of the Chinese people with cardio cerebrovascular diseases based on the similarity analysis through the analysis module, and carry out targeted personalized rehabilitation treatment for different risk groups as early as possible; the disease warning module is used to timely warn and monitor the risk factors of high risk patients with cardio cerebrovascular diseases, so as to achieve timely and effectively interfere the high-risk groups.
Owner:王萍
Molecular markers, internal reference genes and application thereof, detection kit and method for constructing detection model
ActiveCN107574243AImproving technical methods in prognostic predictionMeet the needs of individualized precision treatmentMicrobiological testing/measurementDNA/RNA fragmentationReference genesLow risk group
The invention especially relates to molecular markers, internal reference genes and application thereof, a detection kit and a method for constructing a detection model, belonging to the field of biotechnology. With follow-up information used for comparison, the kit provided by the invention has accuracy of 70% in predication of the risk of recurrence or death of first-visit patients with ER-positive and PR-positive breast cancers in 3-10 years after operations, wherein the prediction accuracies of a low-risk group and a high-risk group are 81.1% and 54.4%, respectively while the prediction accuracies of corresponding FFPE pathological examination results are 71.9 to 56.8%, respectively. The risk prediction model matching with the kit only needs the Ct values of the molecular markers, theage of a patient, the stage of pT and the number of LN and does not depend on other clinical pathological information, so the risk prediction model has better performance in evaluation of prognosis ofbreast cancers than simple pathological prediction results, can reduce malpractice caused by errors in pathological prediction and further improves a technical method for evaluation of prognosis of breast cancers.
Owner:CAPITALBIO CORP +1
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com